news
Nov 18, 2021
Abbott’s Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies’s Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic
J&J intends to split into two companies, separating consumer products and pharmaceutical businesses On November 12, 2021, Johnson & Johnson announced its plans to split the Company’s Consumer Health business, forming a new publicly traded company. This will help the company create two global leaders tha...
Read More...
Nov 16, 2021
AstraZeneca-Moderna’s AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys
AstraZeneca, Moderna announces positive data of mRNA potential in heart failure patients Moderna, Inc., a biotechnology company is pioneering messenger RNA (mRNA) therapeutics and vaccines, declared positive data from the AstraZeneca-led Phase 2 (EPICCURE) study assessing the use of an mRNA therapeutic, wh...
Read More...
Nov 11, 2021
TecTraum’s pro2cool receives Breakthrough Device Designation; Vektor Obtains FDA Clearance for vMap; Medtronic’s TMVR system; Sight Sciences’s PRECISION Trial; Alcon to buy Ivantis; Philips to acquire Cardiologs
TecTraum’s pro2cool® receives FDA Breakthrough Device Designation for the Concussions treatment On November 03, 2021, TecTraum Inc., working to develop the world’s first point-of-care treatment for concussions, announced that the US Food and Drug Administration (FDA) has provided a Breakthrough Device to its f...
Read More...
Nov 09, 2021
Alcon to acquire Ivantis; Philips to takeover Cardiologs; Flunked cancer drug progresses in I-O in pancreatic cancer models; Indigo system CAT RX catheter meets primary endpoint in trial
Alcon to acquire Ivantis for USD 475 Million Alcon announced that it intends to buy glaucoma surgery device maker Ivantis for USD 475 million upfront. Geneva, Switzerland-based Alcon aims to support its portfolio across cataract, refractive, retina and glaucoma offerings by taking over Ivantis and its n...
Read More...
Nov 04, 2021
Smith+Nephew’s LEGION CONCELOC; Renew Bioscience’s Cerezen; Perimeter Medical’s ATLAS AI Project; SAGA Diagnostics-AZ’s Deal; Magnus Receives Breakthrough Device Designation; ReValve’s Transeptal Mitral Valve Replacement
ReValve Solutions, Inc. declares successful first human use of the Transeptal Mitral Valve Replacement On November 01, 2021, ReValve Solutions, Inc., a company operating in the field of transcatheter structural heart replacement and repair, announced the successful first human use of its transcatheter, Palmetto...
Read More...
Nov 02, 2021
Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding
Magnus Medical’s neurostimulation technology gets FDA breakthrough status to treat MDD Magnus Medical has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its neurostimulation technology for major depressive disorder (MDD) treatment. The individualised, rapid-acting...
Read More...
Oct 28, 2021
FDA 510k clearance to Naviswiss’s Naviplan; FDA approved to TYRVAYA; Centinel Spine’s STALIF Integrated Interbody System; Smith+Nephew’s IODOSORB; AlloSource’s AlloMend Extra-Large ADM; SpinaFX and StarFish’s strategic commercialisation contract
Naviswiss secures FDA 510k clearance for Naviplan, an advanced planning solution for hip replacement surgery On October 21, 2021, Naviswiss, a Swiss-based medical technology company, received approval from the FDA to commercialise Naviplan in the United States. Naviplan is a digital pre-operative planning ...
Read More...
Oct 26, 2021
Ocular Therapeutix’s insert fails in phase 2; Click Therapeutics raises $52M funding; Roche introduces AVENIO Tumour Tissue CGP Kit; Blue Wolf Capital to acquire CIVCO Radiotherapy
Ocular Therapeutix’s dry eye disease insert fails in phase 2 trial Ocular Therapeutix declared that its OTX-CSI (cyclosporine intracanalicular insert) for dry eye disease (DED) has flunked to reach the primary endpoint in the phase 2 clinical trial. The company has conducted the US-based, randomised, double-m...
Read More...
Oct 21, 2021
Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech
Hologic to acquire Bolder Surgical for USD160 Million, expanding its Surgical Franchise On October 14, 2021, Hologic, Inc., a global player in women's health, signed a definitive agreement to acquire Bolder Surgical. This US-based company offers advanced energy vessel sealing surgical devices for approxima...
Read More...
Oct 19, 2021
Biogen’s ALS drug Tofersen (BIIB067); Phathom’s erosive esophagitis drug trial; Vertex’s islet cell therapy; Natera launches lung DNA test
Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of Phase III VALOR clinical trial in superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) patients. Althou...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
